ReviewLife metabolism2022
Obesity: an evolutionary context.
Review in Life metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- Short-term effects of weight-loading on heart rate variability in obese adults.Physiological reports · 2026Trial
- Intervening on Calorie Intake or Eating Timing in Older Adults: Lessons Learned in the Healthy Aging and Late-Life Outcomes Randomized Controlled Pilot Trial.Clinical interventions in aging · 2025Trial
- Post-competition recovery in natural physique athletes: body composition, metabolic adaptation, and refeeding responses.Journal of the International Society of Sports Nutrition · 2026Article
- New Challenges and Perspectives in Polycystic Ovary Syndrome.Journal of clinical medicine · 2025Article
- Body weight regulation models in humans: insights for testing their validity.Nature reviews. Endocrinology · 2025Review
- Long-term BMI trajectories and epigenetic age acceleration: the role of genetic risk for obesity.BMC medicine · 2025Article
- Therapeutic Potential of Astaxanthin for Body Weight Regulation: A Systematic Review and Meta-Analysis with Dose-Response Assessment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A Hypothesis on the Historical Development of Obesity that is Not Only About Food.Current obesity reports · 2025Review
- BMI, waist circumference, and waist-to-hip trajectories and all-cause, CVD, and cancer mortality by sex in people without diabetes.International journal of obesity (2005) · 2025Article
- Targeting IGF1 to alleviate obesity through regulating energy expenditure and fat deposition.Science China. Life sciences · 2025Article
- MTCH2 Suppresses Thermogenesis by Regulating Autophagy in Adipose Tissue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.Biomolecules · 2025Review
- Myristoylated Eepd1 Enhances Lipolysis and Thermogenesis through PKA Activation to Combat Obesity.Nature communications · 2025Article
- Appetite-related Gut Hormone Responses to Feeding Across the Life Course.Journal of the Endocrine Society · 2025Review
- The dual burden of obesity: decoding metabolism and female reproductive endocrinology.Frontiers in physiology · 2025Review
- Effects ofFrontiers in physiology · 2025Article
- Reverse epidemiology of obesity paradox: Fact or fiction?Physiological reports · 2024Review
- Enhanced Intrusion of Exogenous Airborne Fine Particles toward Eyes in Humans and Animals: Where Damaged Blood-Ocular Barrier Plays a Crucial Role.Environmental science & technology · 2024Article
- Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.Pharmacology research & perspectives · 2024Review
- Obesity and cardiovascular health.European journal of preventive cardiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
People completely lacking body fat (lipodystrophy/lipoatrophy) and those with severe obesity both show profound metabolic and other health issues. Regulating levels of body fat somewhere between these limits would, therefore, appear to be adaptive. Two different models might be contemplated. More traditional is a set point (SP) where the levels are regulated around a fixed level. Alternatively, dual-intervention point (DIP) is a system that tolerates fairly wide variation but is activated when critically high or low levels are breached. The DIP system seems to fit our experience much better than an SP, and models suggest that it is more likely to have evolved. A DIP system may have evolved because of two contrasting selection pressures. At the lower end, we may have been selected to avoid low levels of fat as a buffer against starvation, to avoid disease-induced anorexia, and to support reproduction. At the upper end, we may have been selected to avoid excess storage because of the elevated risks of predation. This upper limit of control seems to have malfunctioned because some of us deposit large fat stores, with important negative health effects. Why has evolution not protected us against this problem? One possibility is that the protective system slowly fell apart due to random mutations after we dramatically reduced the risk of being predated during our evolutionary history. By chance, it fell apart more in some people than others, and these people are now unable to effectively manage their weight in the face of the modern food glut. To understand the evolutionary context of obesity, it is important to separate the adaptive reason for storing some fat (i.e. the lower intervention point), from the nonadaptive reason for storing lots of fat (a broken upper intervention point). The DIP model has several consequences, showing how we understand the obesity problem and what happens when we attempt to treat it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.